產(chǎn)品名稱

SB 590885

產(chǎn)品貨號

Axon 2504 CAS [405554-55-4] MF C27H27N5O2MW 453.54 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Potent and selective inhibitor of B-Raf kinase (Kd value 0.3 nM for BRAF), devoid of significant activity against a wide panel of enzymes, including p38α, GSK3β, and Lck. SB590885 maintains OCT4-ΔPE-GFP reporter activity and pluripotency gene expression in human ESCs after removal of exogenous KLF2 and NANOG expression, preserving the best colony morphology and proliferation.? SB 590885 is frequently used in a combination of five compounds, including inhibitors of MEK, GSK-3β, BRAF, ROCK, and SRC, which support the expansion of viable OCT4-ΔPE-GFP+ human pluripotent cells after exogenous transcription factor expression has been removed: Axon 2504 SB 590885 BRAF inhibitor Axon 2511 IM 12 GSK-3β inhibitor Axon 1408 PD 0325901 MEK inhibitor Axon 1683 Y 27632 ROCK inhibitor Axon 2381 WH4-023? Lck/Src inhibitor (alternatively, CHIR 99021 (Axon 1386) could be used as GSK-3β inhibitor) Naive Stem Cell 5i inhibitor Set is commercially available (Axon 5011) KEYWORDS: SB 590885 | Supplier | BRAF inhibitor | SB590885 | CAS [405554-55-4] | MEK | RAF | Inhibitor | pluripotent | ESC | stem cell | proliferation | MAPK | cancer | tumor

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

SB 590885

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 2504

CAS [405554-55-4]

MF C27H27N5O2
MW 453.54

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

SB 590885

Description

Potent and selective inhibitor of B-Raf kinase (Kd value 0.3 nM for BRAF), devoid of significant activity against a wide panel of enzymes, including p38α, GSK3β, and Lck. SB590885 maintains OCT4-ΔPE-GFP reporter activity and pluripotency gene expression in human ESCs after removal of exogenous KLF2 and NANOG expression, preserving the best colony morphology and proliferation.?

SB 590885 is frequently used in a combination of five compounds, including inhibitors of MEK, GSK-3β, BRAF, ROCK, and SRC, which support the expansion of viable OCT4-ΔPE-GFP+ human pluripotent cells after exogenous transcription factor expression has been removed:

Axon 2504	SB 590885	BRAF inhibitor
Axon 2511	IM 12	GSK-3β inhibitor
Axon 1408	PD 0325901	MEK inhibitor
Axon 1683	Y 27632	ROCK inhibitor
Axon 2381	WH4-023?	Lck/Src inhibitor

(alternatively, CHIR 99021 (Axon 1386) could be used as GSK-3β inhibitor)

Naive Stem Cell 5i inhibitor Set is commercially available (Axon 5011)

T.W. Theunissen et al. Systematic identification of culture conditions for induction and maintenance of naive human pluripotency. Cell Stem Cell. 2014 Oct 2;15(4):471-87.

A.K. Takle et al. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.

A.J. King et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006 Dec 1;66(23):11100-5.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Stem Cell MAPK EC 2.7.11.1 RAF

Selective inhibitor of B-Raf kinase with application in stem cell therapy

Chemical name

5-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-5-(pyridin-4-yl)-1H-imidazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime

Parent CAS No.

[405554-55-4]

產(chǎn)品資料